|Bid||9,006.00 x 0|
|Ask||9,009.00 x 0|
|Day's range||8,873.00 - 9,029.00|
|52-week range||6,499.80 - 9,081.00|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||41.40|
|Forward dividend & yield||2.02 (2.37%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||N/A|
WILMINGTON, Del., October 20, 2021--AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the third annual Cancer Community Awards (or C2 Awards). A part of the AstraZeneca YOUR Cancer program, the C2 Awards celebrate diverse individuals and organizations creating meaningful change in the lives of people with cancer and their loved ones across five unique categories.
WILMINGTON, Del., October 15, 2021--Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment. This novel dose and schedule
WILMINGTON, Del., October 08, 2021--Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE).